Latest news with #ALD
Scoop
5 days ago
- Politics
- Scoop
Congratulatory Message On Venezuela's Peaceful, Free, Fair, Inclusive, Credible And Democratic Election Process
The Hugo Chavez International Foundation for Peace, Friendship and Solidarity (HCIF-PFS) congratulates Venezuelan people on peaceful, free, fair and credible democratic elections for membership into that country's National Assembly, Governorships and Local Legislative Councils, held on 25th May, 2025. We commend them for their active engagement in the democratic process, and extend warm congratulations to all newly elected representatives of the Venezuelan people at the national, regional and local governance levels. Interestingly, these elections were conducted on the 62nd anniversary of the African Liberation Day (ALD). African Liberation Day, also called African Freedom Day or Africa Day, commemorates the struggle of African people against bondage, oppression, colonialism, apartheid and imperialism. The African people's struggle merges with the struggle for Latin American sovereignty, independence and homeland dignity. So it is not a monolithic celebration of only a political struggle. It is a struggle for cultural freedom as well. Africans situate the continent's Liberation Day not only within the context of the African Union but within the context of the struggle of African people worldwide for emancipation. At least 1, 400 international observers monitored the May 25 elections in Venezuela, according to reports. We note with tremendous admiration the steadfastness, determination, patience and orderliness with which Venezuelan citizens came out and queued to exercise their rights to elect their representatives in tandem with democratic ethos. Though the outcome of the elections was very encouraging, we heard deep concerns of the Venezuelan people regarding attempts by the US government and its proxy institutions, to scuttle the Venezuelan the process. The right to vote during elections is a fundamental human right, and we condemn US policy of destabilization towards Venezuela. We are also concerned about the corporate media's frenzy aimed at misleading public opinion about Venezuela's democracy. We note also the apprehension that gripped the Venezuelan nation in the run off to the polls characterized by right wing political campaigns that were not issued based but laden with incitements, divisive messages, hate speeches, mudslinging, and imperialist-derived and imperialist-driven manifestoes. We therefore celebrate with all Venezuelans that after such a tensed atmosphere, the elections were brought to a peaceful, credible and fair conclusion. Here also, we congratulate and commend the leadership, management and staff members of the Venezuelan National Election Council (CNE), for the doggedness, resolute and commitment to a peaceful, free, fair and credible democratic election, culminating into the emergence of representatives that are really the choice of the Venezuelan people. This we note with credible reports that, election officers at all the polling stations across the country were properly trained in the execution of their duties. In addition, they were courteous and provided assistance to incapacitated voters. They informed voters of the voting process in an impartial and transparent manner. The voting process was therefore conducted according to international procedures and guidelines for the conduct of credible democratic elections. We move forward!
Hype Malaysia
20-05-2025
- Entertainment
- Hype Malaysia
2 Sneaker Drops From Bembury x Crocs & ALD x New Balance Bring Bold Colour & Retro Tech
Want to kick off your sneaker year with a bang? Get ready, because these two drops will fire up your shelf and your socials. From a fingerprint-stamped statement to a sleek retro runner, here's what's dropping. Salehe Bembury x Crocs Pollex Juniper 'Apricot' Salehe Bembury's reign of rubber continues – and this time, he's bringing the heat in juicy 'Apricot.' Following up on his wildly popular Pollex Clog and that quirky 'Art Friends' series (shoutout Nina Chanel Abney), Salehe is back with the fifth iteration of the Pollex Juniper. And yes, it's as delicious as it sounds. This round wraps the upper in an all-over apricot orange, accented with a moody brown tongue and collar, rouge red laces, and a pop of bright blue across the midfoot – it's giving sunset meets streetwear. The real scene-stealer, though? That signature wavy sole, decked out in lavender and stamped with Bembury's iconic fingerprint motif. It's as much a fashion statement as it is a biometric one. Salehe Bembury's Crocs Pollex Juniper 'Apricot' drops 22nd May on BeASpunge, so keep your eyes peeled for price and release updates – this juicy collab won't stay on shelves for long. Aimé Leon Dore x New Balance RC56 If Crocs aren't your jam, maybe something a little more track-to-street will get your engine running. Enter: the Aimé Leon Dore x New Balance RC56. Born from a long-time love affair between the NYC label and Boston's beloved sneaker giant, the RC56 is a brand-new silhouette cooked up in ALD's creative kitchen. Inspired by early 2000s cross-country runners but served with a modern twist, this launch isn't just another collab – it's a straight-up debut. We're getting three clean colourways this week: 'Neon/Grey,' 'Pristine,' and 'Navy' – all laced up in perforated leather, nylon mono mesh, and synthetic detailing. It's giving breathability and bougie. Beneath the surface, FuelCell cushioning and a PU foam footbed offer the kind of plush comfort you'd expect from a long-distance runner. Aimé Leon Dore's New Balance RC56 drops 23rd May, so keep tabs on ALD for the latest scoop on pricing, sizing, and where to snag this clean-cut collab.
Yahoo
20-05-2025
- Health
- Yahoo
Metro Atlanta 4-year-old finishes cancer battle that took more than half his life
After spending more than half of his life battling cancer, a 4-year-old metro Atlanta boy has finished his treatment. Austin Herre rang the bell at Children's Arthur M. Blank Hospital this week after 854 days of treatment. [DOWNLOAD: Free WSB-TV News app for alerts as news breaks] His mother said he was diagnosed with Adrenoleukodystrophy (ALD) at just six months old more than two years ago. ALD is a rare disease that affects 1 in 17,000 people. It's a neurological disorder that affects the adrenal glands and brain and causes long-chain fatty acids in the brain, which destroy the protective myelin sheath around nerve cells responsible for brain function. In January 2023, he was also diagnosed with Acute Lymphoblastic Leukemia. TRENDING STORIES: This metro Atlanta city is ranked No. 1 on new 'Best Places to Live in the U.S.' list Keisha Lance Bottoms makes it official, announces run for Georgia governor Parents sue after they say 6-year-old daughter was racially attacked at school: 'It's disturbing' That same year, he was able to visit a Cherokee County fire station to see some fire trucks and was named an honorary firefighter. Members of the Cherokee County Fire Department reunited with him to be at the ceremony marking the end of his treatment. [SIGN UP: WSB-TV Daily Headlines Newsletter]
Yahoo
19-05-2025
- Health
- Yahoo
Altimmune Announces Initiation of RECLAIM Phase 2 Trial Evaluating the Efficacy and Safety of Pemvidutide in Alcohol Use Disorder (AUD)
GAITHERSBURG, Md., May 19, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced that it has enrolled the first subject in the RECLAIM Phase 2 trial evaluating the efficacy and safety of pemvidutide in subjects with Alcohol Use Disorder (AUD). Pemvidutide is a novel, investigational GLP-1/glucagon dual receptor agonist under development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), obesity, AUD and alcohol liver disease (ALD). IMPACT, a Phase 2b trial of pemvidutide in MASH, is expected to read out topline data in the second quarter of 2025, and a Phase 2 trial of pemvidutide in ALD is expected to initiate enrollment in the third quarter of 2025. RECLAIM is a randomized, placebo-controlled trial being conducted at approximately 15 sites in the United States, with Dr. Henry Kranzler, Karl E. Rickels Professor of Psychiatry and Director, Center for Studies of Addiction at the University of Pennsylvania Perelman School of Medicine, serving as the Principal Investigator. The trial is expected to enroll approximately 100 subjects randomized 1:1 to receive either 2.4 mg pemvidutide or placebo weekly for 24 weeks. The primary endpoint of the trial is a change in alcohol consumption, assessed as the change from baseline in the average number of heavy drinking days per week at Week 24, with the key secondary endpoints including the proportion of subjects achieving a 2-level reduction in World Health Organization (WHO) risk drinking level and the absolute change from baseline in average levels of phosphatidylethanol (PEth), a serum biomarker of alcohol intake. An investigational new drug (IND) application for pemvidutide in AUD was filed in December 2024 and was cleared by FDA in January 2025. 'Over 28 million individuals in the U.S. alone have AUD, and the lack of effective treatments has resulted in one of the largest known treatment gaps in this country,' said Dr. Kranzler. 'It has been estimated that less than 10% of patients are currently receiving treatment for AUD and that 2% or less are being treated with any of the 3 medications approved for AUD in the US1. These medications were approved decades ago and have limited beneficial effects and inadequate compliance rates. Thus, there is an urgent need for new therapies for AUD.' 'There are compelling data that GLP-1 agents may reduce the craving for alcohol in addition to reducing food consumption,' said Scott Harris, M.D., Chief Medical Officer of Altimmune. 'In a preclinical hamster model of free-choice alcohol intake, pemvidutide demonstrated a greater than 80% reduction in alcohol preference after the initiation of treatment2. Importantly, AUD is the precursor for alcohol liver disease (ALD), a disease characterized by excess liver fat, liver inflammation and fibrosis with features similar to MASH. In addition, obesity is a major risk factor for MASH, AUD and ALD, and because excess alcohol is a known risk factor for hypertension and dyslipidemia, patients with AUD could benefit further from the metabolic effects of pemvidutide.' About Altimmune Altimmune is a late clinical-stage biopharmaceutical company focused on developing novel peptide-based therapeutics for liver and cardiometabolic diseases. The Company's lead program is pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of MASH, obesity, Alcohol Use Disorder (AUD) and Alcohol Liver Disease (ALD). For more information, please visit Follow @Altimmune, Inc. on LinkedInFollow @AltimmuneInc on X Forward-Looking StatementAny statements made in this press release related to the development or commercialization of product candidates and other business and financial matters, including without limitation, trial results and data, the timing of key milestones for our clinical assets, and the prospects for the utility of, regulatory approval, commercializing or selling any product or drug candidates, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In addition, when or if used in this press release, the words "may," "could," "should," "anticipate," "believe," "estimate," "expect," "intend," "plan," "predict" and similar expressions and their variants, as they relate to Altimmune, Inc. may identify forward-looking statements. The Company cautions that these forward-looking statements are subject to numerous assumptions, risks, and uncertainties, which change over time. Important factors that may cause actual results to differ materially from the results discussed in the forward looking statements or historical experience include risks and uncertainties, including risks relating to: delays in regulatory review, manufacturing and supply chain interruptions, access to clinical sites, enrollment, adverse effects on healthcare systems and disruption of the global economy; the reliability of the results of studies relating to human safety and possible adverse effects resulting from the administration of the Company's product candidates; the Company's ability to manufacture clinical trial materials on the timelines anticipated; and the success of future product advancements, including the success of future clinical trials. Further information on the factors and risks that could affect the Company's business, financial conditions and results of operations are contained in the Company's filings with the U.S. Securities and Exchange Commission, including under the heading "Risk Factors" in the Company's most recent annual report on Form 10-K and our other filings with the SEC, which are available at Company Contact:Greg WeaverChief Financial OfficerPhone: 240-654-1450ir@ Investor Contact:Lee RothBurns McClellanPhone: 646-382-3403lroth@ Media Contact:Jake RobisonInizio Evoke, BiotechPhone: 1 SAMHSA 2023 NSDUH Survey 2 Altimmune R&D Day Presentation, slide #47 This press release was published by a CLEAR® Verified individual.
Yahoo
14-05-2025
- Business
- Yahoo
Altimmune Inc (ALT) Q1 2025 Earnings Call Highlights: Financial Strength and Strategic Developments
Cash Position: Ended Q1 2025 with $150 million in cash, cash equivalents, and short-term investments, up from $132 million at year-end 2024. ATM Facility: Raised $35 million net in Q1 2025, with an additional $16 million since April 1. Credit Facility: Entered into a $100 million credit facility with Hercules Capital, with $15 million funding at closing and additional tranches available. R&D Expenses: $15.8 million for Q1 2025, down from $21.5 million in Q1 2024. G&A Expenses: $6 million for Q1 2025, up from $5.3 million in Q1 2024. Net Loss: $19.6 million or $0.26 per share for Q1 2025, compared to $24.4 million or $0.34 per share in Q1 2024. Warning! GuruFocus has detected 3 Warning Signs with ALT. Release Date: May 13, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Altimmune Inc (NASDAQ:ALT) is optimistic about the upcoming readout of their IMPACT Phase 2b NASH trial, expecting to achieve key efficacy and safety objectives. The company has entered into a $100 million credit facility with Hercules Capital, enhancing financial flexibility for the development of pemvidutide. Altimmune Inc (NASDAQ:ALT) is expanding its clinical trials to include alcohol use disorder (AUD) and alcohol liver disease (ALD), addressing significant unmet medical needs. The company reported a strong cash position, ending the first quarter with $150 million in cash, cash equivalents, and short-term investments. Altimmune Inc (NASDAQ:ALT) is preparing for a Phase 3 trial in NASH, with plans to hold an end of Phase 2 meeting with the FDA in the fourth quarter of 2025. The company faces risks and uncertainties that could cause actual results to differ materially from forward-looking statements. R&D expenses decreased from $21.5 million in Q1 2024 to $15.8 million in Q1 2025, which might indicate reduced investment in research and development. Net loss for the first quarter of 2025 was $19.6 million, indicating ongoing financial challenges. The company is still in the process of rereading biopsies for the IMPACT trial, which could affect the timeline and outcomes. There is uncertainty regarding the placebo response rate in the IMPACT trial, which could impact the trial's success. Q: Can you provide commentary on the distribution of F2 and F3 in the Phase 2b population and how representative it is compared to other successful Phase 2b studies? A: We are in the final stages of rereading the biopsies, so we can't provide precise numbers yet. However, the demographics, including age, sex, F2/F3 distribution, and other characteristics, are very similar to other studies, making our data meaningful and comparable. - Scott Harris, Chief Medical Officer Q: What is the ideal patient population for pemvidutide in MASH, and are there any partnership opportunities being considered? A: We are targeting MASH with obesity, as 80-90% of MASH patients are obese. Pemvidutide addresses both obesity and liver fibrosis, offering a comprehensive treatment. Regarding partnerships, we are open to discussions but are prepared to move forward with Phase 3 development independently. - Vipin Garg, Chief Executive Officer Q: How are discontinuations being handled in the study, and what is the expected placebo response range? A: Discontinuations are being managed well, and we are pleased with the data so far. Placebo responses have varied widely in past trials, but with our methodology, we expect to see a placebo response rate between 7% and 13%. - Scott Harris, Chief Medical Officer Q: How important is weight loss in the study, and what weight loss should be expected compared to semaglutide? A: Weight loss is crucial, especially for patients with obesity and cardiovascular risks. We expect clinically significant weight loss similar to semaglutide, which showed about 10% weight loss at 72 weeks. Our 24-week results should be comparable, providing a complete solution for MASH. - Scott Harris, Chief Medical Officer Q: What are the plans for Phase 3, and how might the development timeline be shortened? A: We are considering using a higher dose in Phase 3 for better weight loss and potentially having a six-month endpoint to accelerate the timeline. We plan to discuss these options with the FDA in the fourth quarter. - Scott Harris, Chief Medical Officer For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Sign in to access your portfolio
